Acute kidney injury during ruxolitinib therapy in pediatric patients with graft-versus-host disease: incidence, associated factors, and histopathological findings in a retrospective cohort study
BK virus reactivation, BKV-related hemorrhagic cystitis, CMV reactivation, older age at transplantation, and higher baseline creatinine were significantly associated with AKI, whereas ruxolitinib dose was not, whereas ruxolitinib dose was not.
Abstract
Abstract Ruxolitinib is a cornerstone treatment for steroid-refractory graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) in children, yet longitudinal data on kidney function during such therapy remain limited. We retrospectively analyzed 38 pediatric patients (0–18 years) receiving ruxolitinib for acute or chronic GVHD between January 2018 and December 2025, assessing kidney function at six timepoints from baseline to month 6. Mean serum creatinine rose from 0.34 ± 0.16 mg/dL at baseline to 0.50 ± 0.34 mg/dL at month 3 (p < 0.001) and remained mildly elevated at month 6 (0.48 ± 0.23 mg/dL; p < 0.001). Acute kidney injury (AKI) occurred in 7 patients (18.4%) at a median of 2.36 months after ruxolitinib initiation, with 4 (57.1%) progressing to acute kidney disease; biopsies excluded BK virus nephropathy. BK virus reactivation, BKV-related hemorrhagic cystitis, CMV reactivation, older age at transplantation, and higher baseline creatinine were significantly associated with AKI, whereas ruxolitinib dose was not. Post-transplant AKI in this setting appears multifactorial; controlled studies including a ruxolitinib-unexposed comparator group are needed to clarify the specific contribution of the drug.
Background/Objectives: Kidney-related complications contribute substantially to morbidity in children undergoing hematopoietic stem cell transplantation (HSCT), although evidence in pediatric populations remains limited. This study aimed to evaluate the incidence of acute kidney injury (AKI), chronic kidney disease (CK...
B. Macit, A. Akyay, Yurday Öncül et al.· Journal of Clinical Medicine· 0 citations
BACKGROUND
Graft-versus-host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T-cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited.
PROCEDURE
A systematic review and meta...
M. Kruizinga, Anne B. Verbeek, C. Lindemans et al.· Pediatric Blood & Cancer· 0 citations
BACKGROUND
Acute graft-versus-host disease (aGVHD) remains a leading cause of non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). On the cyclosporine A (CsA)/methotrexate (MTX)/mycophenolate mofetil (MMF) backbone, MMF withdrawal around engraftment creates an immunosuppress...
Huan Hua, Xuan Liu, Shu-Peng Wen et al.· Transplantation and Cellular...· 0 citations
PURPOSE
This trial evaluated whether the addition of sitagliptin to antithymocyte globulin (ATG)-based prophylaxis reduces the incidence of acute graft-versus-host disease (aGVHD) after alternative donor hematopoietic stem-cell transplantation.
METHODS
This prospective, multicenter, open-label, randomized trial enrol...
Man Qiao, Bi-Qi Zhou, Yi-Yin Chen et al.· Journal of Clinical Oncology· 0 citations
Background/Objectives: Hematopoietic cell transplantation (HCT) is the only established curative option for sickle cell disease (SCD), yet the optimal timing in pediatric cohorts remains incompletely defined. Methods: We retrospectively analyzed all patients under 20 years with SCD who underwent HCT at the University H...
C. Nazon, Chloé Gerber, Alexandra Salmon et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.